What Happened

Mirum Pharmaceuticals and Incyte announced pivotal Phase 2 results for zilurgisertib, demonstrating a 99.9% reduction in new HO lesions in FOP patients. The FDA granted Priority Review for the NDA, with a PDUFA target action date of September 26, 2026.

Who Is Affected

Adolescents and adults (≥12 years of age) with fibrodysplasia ossificans progressiva (FOP) are the primary beneficiaries of this treatment. The PROGRESS study included 63 patients, showing significant efficacy and tolerability.

Market Impact

• Potential new treatment option for FOP patients.
• Increased focus on rare disease treatments.
• Opportunity for partnerships and collaborations in the biotech sector.

What to Watch

Monitor the FDA's decision on the NDA by September 26, 2026. Additionally, track further clinical trials and potential commercialization efforts by Mirum Pharmaceuticals and Incyte.